The U.S. Market for Over-the-Counter Anti-Infectives

Table of Contents

Chapter One: Executive Summary

• Report Scope
• Categories
• Methodology
• Product Description
  • Overview
  • Antiseptics
  • Antibiotics
  • Antifungal Treatments
  • Anti-Parasitic (Lice) Treatments
• The Market
• Market Composition
• Key Trends & Issues
  • Seasonality in Anti-fungal Treatment Sales
  • Most Drugs Approved in 2004 Since 1996
  • Lack of Rx-to-OTC Switches for Anti-infectives
  • Growing Healthcare Costs
• The Online Healthcare Market
  • The Growth of Generics
• Market Forecast
  • The Marketers
  • Private Labels
• The Consumer
  • Marketing Dynamics

Chapter Two: The Market

• Product Description
  • Overview
  • Antiseptics
  • Antibiotics
  • Antibiotic Resistance
  • Antifungal Treatments
• Introduction to Infections
  • Jock Itch (Tinea Cruris)
  • Vaginal Yeast Infection (Vulvovaginal Candidiasis)
  • Athlete’s Foot (Tinea Pedis)
  • Antiparasitic (Lice) Treatments
  • Regulatory Environment
  • Brand and Generic Names
  • The Cost Factor
  • Approval Process
• OTC and Prescription Drugs
• Rx-to-OTC Switch
  • Labeling Issues
  • Industry Overview
  • Market Composition
  • Anti-fungal Treatment
  • First Aid Products
  • Anti-Parasitic Treatments
• Key Trends & Issues
  • Seasonality in Antifungal Treatment Sales
  • Number of New Drug Approvals
  • More Botanicals, Fewer Preservatives
  • Lack of Rx-to-OTC Switches for Anti-Infectives
  • Growing Healthcare Costs
  • Children — A Key Demographic
  • Growing Insurer Share in Healthcare
  • Pharma’s Revenue Expectations
  • Importation of Drugs
  • Growing Share of Uninsured Population
  • Lower Drug Costs Through Outsourcing
  • Consumer Acceptance of Self-Medication
  • The Online Healthcare Market
  • The Insurer Push
  • Direct-to-Consumer Advertising
  • The Growth of Generics
• Market Forecast

Chapter Three: The Marketers

Competitive Analysis

• Top Marketers and Products

Antifungal Treatments

• Flat Sales for Jock Itch Brands
• Lotrimin Ultra Outperforms Category
• Monistat Dominates Yeast Infection Treatments
• Athlete’s Foot — Schering-Plough at the Top

Antiseptics/Antibiotics

• First Aid Brands Thrive

Anti-Parasitics

• Lice Treatments Suffer

Private Labels

Mergers & Acquisitions

• Pfizer Acquires Pharmacia Corp.
• Novartis AG – Eon Labs
• Novartis Acquires Vagistat from Bristol-Myers Squibb
• Mylan Laboratories Acquires King Pharmaceuticals

Chapter Four: The Consumer

• Simmons Survey
• Overview
• First Aid
  • First Aid Bandages
  • Sprays, Gels & Wipes Emerging
  • Band-Aid, The Consumer’s Favorite
• Antifungal Treatments
  • Foot and Nail Fungus
  • Older Population
  • Roper Public Affairs Survey
  • Men more Likely to Suffer from Athlete’s Foot
  • Central and Pacific States Index Higher for Athlete’s Foot
  • Foot Problem Survey
  • Athlete’s Foot & Nail Fungus Treatment Users
  • Yeast Infection
  • Yeast Treatment Usage by Type
  • African-American Women Index Higher
  • Monistat Leads All
• Consumer Attitudes
  • Preference for OTC Drugs and Private Labels
  • Store Brand Buyers
• 
  Chapter Five: Marketing Dynamics
  • Overview
  • Advertising and Promotion
    • Pfizer Tops Ad Spend List
    • Novartis’ DTC Campaign
    • Monistat Intimate Skincare Launch
  • Distribution & Retailing
    • Drug Store Chains
    • e-Pharmacies
  • Retail trends
    • Drug Stores Outpace Overall Market
  • Store Clinics
    • Rite Aid Tests Hispanic Stores
    • Drug Chains Aid Consumers
    • Pharmacy Recommendations
    • Walgreens’ Health Initiatives
  • New Product Introductions
    • Consumers Prefer Quick-Relief & Natural Products
    • First Aid for Kids
    • Limited Yeast Infection Products
    • Hypoallergenic Anti-Infectives
    • Scented/Flavored Products
  • Innovation
    • Curad Bandages
    • Brand
  • 
    Chapter Six: Company Profiles
  • Johnson & Johnson
    • Overview
    • OTC Anti-Infective Product Line
    • Band-Aid
    • Monistat
    • Performance
  • Pfizer Inc.
    • Overview
    • OTC Anti-Infective Product Line
    • Focus on Pharmaceuticals and Healthcare
    • Performance
  • Bayer Group
    • Overview
    • U.S. Operations
    • OTC Anti-Infective Product Line
    • Performance
    • Bayer, Expanding its Reach
  • Bristol-Myers Squibb Company
    • Overview
    • OTC Anti-Infectives
    • Performance
    • Renewed Strategy – Focus on Prescription Drugs
  • Novartis AG
    • Overview
    • The Consumer Health Division
    • OTC Anti-Infective Product Line
    • Performance
    • R&D: The Company’s Lifeblood
  • Schering Plough Corporation
    • Overview
    • OTC Anti-Infective Product Line
    • Performance
  • Combe Inc.
    • Overview
    • OTC Anti-Infective Product line
    • Performance
  • Chattem Inc.
    • Overview
    • OTC Anti-Infective Product Line
  • Performance
    • Future Strategy
  • Merz Pharmaceuticals
    • Overview
    • Performance
  • Beiersdorf AG
    • Overview
    • OTC Anti-Infective Product Line
    • Performance
    • Future Strategy
  • Taro Pharmaceuticals Industries Ltd.
    • Overview
    • R&D
    • Drug Portfolio
    • Performance
    • FDA Approves Taro’s Mupirocin Ointment
  • Stiefel Laboratories Inc.
    • Overview
    • Skin Care Products
    • Sarna #1 Itch Relief Cream for 3 Years
    • Performance
    • FDA Approval for MimyX Cream
  • Alva-Amco Pharmacal Companies Inc.
    • Overview
    • Product Portfolio
    • Performance
    • FungiCure 2004 Nail Hygiene Survey
  • Becton Dickinson & Company
    • Overview
    • Anti-Infective Products
    • Performance
    • FDA Approval for BD Diagnostic Products
  • Playtex Products Inc.
    • Overview
    • Product Portfolio
    • Performance
    • Core Category Acquisitions
  • 
    Appendix: Addresses of Select Marketers

  • List of Exhibits
  • Chapter One: Executive Summary
    • Table 1-1: U.S. Retail OTC Anti-Infective Sales 2000-2005
    • Table 1-2: IRI-Tracked Retail Anti-Infective Category Sales 2005
    • Table 1-3: IRI-Tracked Retail Sales of U.S. Top 10 Anti-Infective Marketers 2004-2005
    • Table 1-4: IRI-Tracked Retail Sales of U.S. Top 10 Anti-Infective Brands 2004-2005

Chapter Two: The Market

• Table 2-1: Stages in Clinical Trial
• Figure 2-1: U.S. Drug Development and Patent Process
• Figure 2-2: U.S. OTC Review Process
• Figure 2-3: U.S. Retail OTC Anti-infective Sales, 2000-2005 (E)
• Table 2-2: IRI-Tracked U.S. Retail Sales of OTC Anti-Infectives by Category (Antifungals, First Aid, Antiparasitics) 2000-2005 (E)
• Table 2-3: IRI-Tracked U.S. Retail OTC Anti-Infective Category Shares 2000-2005 (E)
• Table 2-4: IRI-Tracked U.S. Retail Sales of OTC Antifungals by Infection Type (Athlete’s Foot, Jock Itch, Vaginal Yeast Infection) 2000-2005 (E)
• Figure 2-4: IRI-tracked U.S. Jock Itch and Athlete’s Foot Quarterly Sales, 2004-2005
• Table 2-5: U.S. Top 10 Cities Estimated to Experience Itch-Related Infections, 2005
• Figure 2-5: U.S. FDA Drug Approvals, 1991-2004
• Figure 2-6: National Health Expenditure, 1993-2003
• Table 2-6: Projected U.S. Health Expenditures and Per Capita Income 2005-2010
• Table 2-7: Younger U.S. Population (Under 15 Years) Projections 2000-2030
• Table 2-8: Birth Rate and Women Age Group, 2002-2003
• Figure 2-7: Spending for Prescription Drugs by Source of Funds (%)
• Table 2-9: Uninsured Population by Age Group, 2003
• Table 2-10: U.S. Generic Drug vs. Branded Drug Performance
• Table 2-11: U.S. Top Five Generic Drug Marketers 2004 (Sales, Market Share, Growth from 2003)
• Figure 2-8: U.S. Retail Anti-Infective Sales Projections, 2005-2010 (E)
• Table 2-12: U.S. Retail Anti-Infective Sales Projections by Category 2005-2010 (E)

Chapter Three: The Marketers

• Table 3-1: IRI-Tracked Sales of Top 10 U.S. OTC Anti-Infective Marketers 2000-2005 (E)
• Figure 3-1: U.S. Top 10 OTC Anti-Infective Marketers by Market Share 2005 (E)
• Table 3-2: IRI-Tracked Sales of Top 10 U.S. OTC Anti-Infective Brands 2000-2005 (E)
• Table 3-3: IRI-Tracked Sales of Top 10 U.S. OTC Antifungal Marketers 2000-2005 (E)
• Table 3-4: U.S. Top 10 Antifungal Marketers by Market Share 2000-2005 (E)
• Table 3-5: IRI-Tracked Sales of Top 10 U.S. OTC Antifungal Brands 2000-2005 (E)
• Table 3-6: IRI-Tracked Sales of Top 10 U.S. OTC Jock Itch Treatment Marketers, 2000-2005 (E)
• Table 3-7: U.S. Top 10 OTC Jock Itch Treatment Marketers by Market Share, 2000-2005 (E)
• Table 3-8: IRI-Tracked Sales of Top 10 U.S. OTC Jock Itch Treatment Brands 2000-2005 (E)
• Table 3-9: Top 10 Recognized Dermatology Brands in North America, 2005
• Table 3-10: IRI-Tracked Sales of Top 10 U.S.OTC Vaginal Yeast Infection Treatment Marketers 2000-2005 (E)
• Table 3-11: U.S. Top 10 Vaginal Yeast Infection Treatment Marketers by Market Share, 2000-2005 (E)
• Table 3-12: IRI-Tracked Sales of Top 10 U.S. OTC Vaginal Yeast Infection Treatment Brands, 2000-2005 (E)
• Table 3-13: IRI-Tracked Sales of Top 10 U.S. OTC Athlete’s Foot Treatment Marketers, 2000-2005 (E)
• Table 3-14: U.S. Top 10 Athlete’s Foot Treatment Marketers by Market Share, 2000-2005 (E)
• Table 3-15: IRI-Tracked Sales of Top 10 U.S. OTC Athlete’s Foot Treatment Brands, 2000-2005 (E)
• Table 3-16: IRI-Tracked Sales of Top 10 U.S. OTC Antiseptic/Antibiotic Marketers, 2000-2005 (E)
• Table 3-17: U.S. Top 10 Antiseptic/Antibiotic Marketers by Market Share, 2000-2005 (E)
• Table 3-18: IRI-Tracked Sales of Top 10 U.S. OTC Antiseptic/Antibiotic Brands, 2000-2005 (E)
• Table 3-19: IRI-Tracked Sales of Top 10 U.S. OTC Anti-Parasitic Treatment Marketers, 2000-2005 (E)
• Table 3-20: U.S. Top 10 Anti-Parasitic Treatment Marketers by Market Share 2000-2005 (E)
• Table 3-21: IRI-Tracked Sales of Top 10 U.S. OTC Anti-Parasitic Treatment Brands, 2000-2005 (E)
• Figure 3-2: U.S. Private Label OTC Anti-Infective Sales, 2000-2005 (E)
• Table 3-22: IRI-Tracked Sales of U.S. Private Label OTC Anti-Infectives by Category (Antiseptics/Antibiotics, Anti-fungal Treatments, Antiparasitic Treatments) 2000-2005 (E)
• Table 3-23: U.S. Private Label OTC Anti-Infective Market Share by Category (Antiseptics/Antibiotics, Anti-fungal Treatments, Antiparasitic Treatments) 2000-2005 (E)

Chapter Four: The Consumer

• Figure 4-1: U.S. Usage of First Aid Products, 2004 (%)
• Figure 4-2: U.S. Usage of First Aid Products by Gender, 2005 (%)
• Table 4-1: U.S. Usage of First Aid Bandages by Age, 2005
• Table 4-2: U.S. Usage of First Aid Bandages, by Ethnicity, 2005
• Figure 4-3: U.S. Usage of First Aid Products by Type, 2005
• Table 4-3: U.S. Usage of First Aid Sprays, Gels and Wipes by Household Size, 2005
• Table 4-4: U.S. Usage of First Aid Sprays, Gels and Wipes by Age of Children, 2005
• Figure 4-4: U.S. First Aid Brands Used, 2005
• Table 4-5: Demographic Profile of U.S. First Aid Product Users, 2005
• Table 4-6: Demographic Profile of U.S. First Aid Cream, Gel and Liquid Users, 2005
• Table 4-7: Demographic Profile of U.S. First Aid Ointment, Spray, Stick and Wipe Users, 2005
• Table 4-8: Demographic Profile of U.S. First Aid Users by Brand, 2005
• Table 4-9: Demographic Profile of U.S. Store Brand First Aid Product Users, 2005
• Table 4-10: U.S. Prevalence of Athlete’s Foot by Age, 2005
• Figure 4-5: U.S. Prevalence of Athlete’s Foot by Gender, 2005
• Figure 4-6: U.S. Prevalence of Nail Fungus by Gender, 2005
• Table 4-11: U.S. Prevalence of Athlete’s Foot and Nail Fungus by Ethnicity, 2005
• Table 4-12: U.S. Prevalence of Athlete’s Foot and Nail Fungus by Region, 2005
• Table 4-13: U.S. Prevalence of Athlete’s Foot and Nail Fungus by Education, 2005
• Table 4-14: U.S. Foot Problem Prevalence, 2004
• Table 4-15: Demographic Profile of U.S. Athlete’s Foot Treatment User, 2005
• Table 4-16: Demographic Profile of U.S. Nail Fungus Treatment User, 2005
• Table 4-17: Demographic Profile of U.S. Athlete’s Foot-Infected Consumer, 2005
• Table 4-18: Demographic Profile of U.S. Nail Fungus-Infected Consumer, 2005
• Table 4-19: Demographic Profile of U.S. Women Using Yeast Infection Products, 2005
• Table 4-20: Yeast Infection Treatment by Type Preferred (1, 3, and 7-Day) 2005
• Table 4-21: Yeast Infection Treatment Usage by Ethnicity, 2005
• Figure 4-7: U.S. Yeast Infection Brands Used, 2005
• Table 4-22: Demographic Profile of U.S. Yeast Infection Treatment User by Treatment Type, 2005
• Table 4-23: Demographic Profile of U.S. Yeast Infection Treatment User by Brand, 2005
• Table 4-24: U.S. Consumer Attitudes w.r.t. Healthcare and Drugs, 2005
• Table 4-25: Demographic Profile of U.S. Consumers Based on Attitude Towards Store Brands, 2004

Chapter Five: Marketing Dynamics

• Table 5-1: Ad Spend of Top 10 U.S. OTC Anti-Infective Marketers 2004
• Table 5-2: Ad Spend and Media Channel of Top 10 U.S. OTC Anti-Infective Brands 2004
• Table 5-3: U.S. Sales of Select OTC Anti-Infective Categories Through Drug Stores 2004
• Table 5-4: Top Pharmacist Recommended Adhesive Bandages, 2005
• Table 5-5: Top Pharmacist Recommended Athlete’s Foot Treatments, 2005
• Table 5-6: Top Pharmacist Recommended Jock Itch Treatments, 2005
• Table 5-7: Top Pharmacist Recommended Lice Treatments, 2005
• Table 5-8: Top Pharmacist Recommended Nail Fungus Treatments, 2005
• Table 5-9: Top Pharmacist Recommended Scar Treatments, 2005
• Table 5-10: Top Pharmacist Recommended Vaginal Antifungals, 2005
• Table 5-11: Top Pharmacist Recommended Wound Treatments, 2005
• Table 5-12: Top 10 Marketers by Total SKUs Launched, 2005
• Table 5-13: Top 10 Brands by Total SKUs Launched, 2005
• Table 5-14: Top 10 Package Tags by Number of Brands, 2005
• Table 5-15: U.S. Anti-Infective Product Introductions Tagged ‘Instant/Quick’, 2005
• Table 5-16: U.S. Anti-Infective Product Introductions Tagged ‘Natural/Pure/Organic*’, 2005
• Table 5-17: U.S. Anti-Infective Product Introductions for Teens/Kids, 2005
• Table 5-18: U.S. Anti-Infective Product Introductions Tagged ‘Upscale’, 2005
• Table 5-19: U.S. Anti-Infective Product Introductions for Women, 2005
• Table 5-20: U.S. Anti-Infective Product Introductions Tagged ‘No Allergy’, 2005
• Table 5-21: U.S. Anti-Infective Product Introductions Tagged ‘High Vitamins’, 2005
• Table 5-22: Top 10 OTC Anti-Infective Flavors/Fragrances, 2005
• Table 5-23: U.S. Anti-Infective Product Introductions Flavored/Scented ‘Blend’, 2005
• Table 5-24: U.S. Anti-Infective Product Introductions Flavored/Scented ‘Lavender’, 2005
• Table 5-25: U.S. Anti-Infective Product Introductions by Innovation, 2005

Chapter Six: Company Profiles

• Table 6-1: Johnson & Johnson OTC Anti-Infective Brand Portfolio
• Figure 6-1: IRI-Tracked U.S. Anti-infective Sales of J ohnson & Johnson 2000-2005 (E)
• Table 6-2: Pfizer Inc. OTC Anti-infective Brand Portfolio
• Figure 6-2: Pfizer OTC Anti-infective Category Shares, 2005 (E)
• Figure 6-3: IRI-Tracked U.S. Anti-infective Sales of Pfizer Inc., 2000-2005 (E)
• Table 6-3: Bayer OTC Anti-infective Brand Portfolio
• Figure 6-4: Bayer OTC Anti-infective Category Shares, 2005 (E)
• Figure 6-5: IRI-Tracked U.S. Anti-infective Sales of Bayer, 2000-2005 (E)
• Figure 6-6: IRI-Tracked U.S. Anti-infective Sales of Bristol-Myers Squibb, 2000-2005 (E)
• Table 6-4: Novartis AG OTC Anti-infective Brand Portfolio
• Figure 6-7: IRI-Tracked U.S. Anti-infective Sales of Novartis AG, 2000-2005 (E) 198
• Table 6-5: Bayer Anti-infective Brand Portfolio
• Figure 6-8: Schering-Plough Corporation OTC Anti-infective Category Shares, 2005 (E)
• Figure 6-9: IRI-Tracked U.S. Anti-infective Sales of Schering Plough, 2000-2005 (E)
• Table 6-6: Combe Inc. OTC Anti-infective Brand Portfolio
• Figure 6-10: Combe Inc. OTC Anti-infective Category Shares, 2005 (E)
• Figure 6-11: IRI-Tracked U.S. Anti-infective Sales of Combe Inc., 2000-2005 (E)
• Figure 6-12: Chattem Inc. Business Segments as Percentage of Worldwide Sales, 2004
• Figure 6-13: Chattem Inc. OTC Anti-infective Category Shares, 2005 (E)
• Figure 6-14: IRI-Tracked U.S. Anti-infective Sales of Chattem Inc., 2000-2005 (E)
• Figure 6-15: IRI-Tracked U.S. Anti-infective Sales of Merz Pharmaceuticals, 2000-2005 (E)
• Table 6-7: Beiersdorf Inc. OTC Anti-infective Brand Portfolio
• Figure 6-16: Beiersdorf Inc. OTC Anti-infective Category Shares, 2005 (E)
• Figure 6-17: IRI-Tracked U.S. Anti-infective Sales of Beiersdorf Inc., 2000-2005 (E)
• Figure 6-18: IRI-Tracked U.S. Anti-infective Sales of Taro Pharmaceuticals, 2000-2005 (E)
• Figure 6-19: IRI-Tracked U.S. Anti-infective Sales of Stiefel Laboratories, 2000-2005 (E)
• Figure 6-20: IRI-Tracked U.S. Anti-infective Sales of Alva-Amco Pharmacal, 2000-2005 (E)
• Table 6-8: Becton Dickinson Company Sales, by Region, 2004
• Table 6-9: Becton Dickinson Company Sales, by Division, 2004 Figure 6-21: IRI-Tracked U.S. Anti-infective Sales of Becton Dickinson, 2000-2005 (E)
• Table 6-10: Playtex Products Inc. Sales, by Division, 2004
• Figure 6-22: IRI-Tracked U.S. Anti-infective Sales of Playtex Products, 2000-2005 (E)